 | • レポートコード：GIR-107A11951 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、卵巣がん治療・診断のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。卵巣がん治療・診断の種類別市場規模（手術、放射線療法、薬物治療）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・卵巣がん治療・診断の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Astra Zeneca、Clovis Oncology、Myriad、TESARO、AbbVie Inc、Celgene、Janssen Pharmaceuticals、Merck、Novartis AG、Quest Diagnostics Inc ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：手術、放射線療法、薬物治療 ・用途別分析2016年-2026年：病院、クリニック、その他 ・卵巣がん治療・診断の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・卵巣がん治療・診断のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・卵巣がん治療・診断のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・卵巣がん治療・診断の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・卵巣がん治療・診断の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Therapies and Diagnostics for Ovarian Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Therapies and Diagnostics for Ovarian Cancer size is estimated to be USD 2388.1 million in 2026 from USD 2055 million in 2020, with a change XX% between 2020 and 2021. The global Therapies and Diagnostics for Ovarian Cancer market size is expected to grow at a CAGR of 3.8% for the next five years.
Market segmentation
Therapies and Diagnostics for Ovarian Cancer market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Surgery
Radiation Therapy
Drug Treatment
Market segment by Application, can be divided into
Hospitals
Clinics
Others
Market segment by players, this report covers
Astra Zeneca
Clovis Oncology
Myriad
TESARO
AbbVie Inc
Celgene
Janssen Pharmaceuticals
Merck
Novartis AG
Quest Diagnostics Inc
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Therapies and Diagnostics for Ovarian Cancer
1.2 Classification of Therapies and Diagnostics for Ovarian Cancer by Type
1.2.1 Overview: Global Therapies and Diagnostics for Ovarian Cancer Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Type in 2020
1.2.3 Surgery
1.2.4 Radiation Therapy
1.2.5 Drug Treatment
1.3 Global Therapies and Diagnostics for Ovarian Cancer Market by Application
1.3.1 Overview: Global Therapies and Diagnostics for Ovarian Cancer Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Therapies and Diagnostics for Ovarian Cancer Market Size & Forecast
1.5 Global Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast by Region
1.5.1 Global Therapies and Diagnostics for Ovarian Cancer Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Therapies and Diagnostics for Ovarian Cancer Market Size by Region, (2016-2021)
1.5.3 North America Therapies and Diagnostics for Ovarian Cancer Market Size and Prospect (2016-2026)
1.5.4 Europe Therapies and Diagnostics for Ovarian Cancer Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size and Prospect (2016-2026)
1.5.6 South America Therapies and Diagnostics for Ovarian Cancer Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Therapies and Diagnostics for Ovarian Cancer Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Therapies and Diagnostics for Ovarian Cancer Market Drivers
1.6.2 Therapies and Diagnostics for Ovarian Cancer Market Restraints
1.6.3 Therapies and Diagnostics for Ovarian Cancer Trends Analysis
2 Company Profiles
2.1 Astra Zeneca
2.1.1 Astra Zeneca Details
2.1.2 Astra Zeneca Major Business
2.1.3 Astra Zeneca Therapies and Diagnostics for Ovarian Cancer Product and Solutions
2.1.4 Astra Zeneca Therapies and Diagnostics for Ovarian Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Astra Zeneca Recent Developments and Future Plans
2.2 Clovis Oncology
2.2.1 Clovis Oncology Details
2.2.2 Clovis Oncology Major Business
2.2.3 Clovis Oncology Therapies and Diagnostics for Ovarian Cancer Product and Solutions
2.2.4 Clovis Oncology Therapies and Diagnostics for Ovarian Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Clovis Oncology Recent Developments and Future Plans
2.3 Myriad
2.3.1 Myriad Details
2.3.2 Myriad Major Business
2.3.3 Myriad Therapies and Diagnostics for Ovarian Cancer Product and Solutions
2.3.4 Myriad Therapies and Diagnostics for Ovarian Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Myriad Recent Developments and Future Plans
2.4 TESARO
2.4.1 TESARO Details
2.4.2 TESARO Major Business
2.4.3 TESARO Therapies and Diagnostics for Ovarian Cancer Product and Solutions
2.4.4 TESARO Therapies and Diagnostics for Ovarian Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 TESARO Recent Developments and Future Plans
2.5 AbbVie Inc
2.5.1 AbbVie Inc Details
2.5.2 AbbVie Inc Major Business
2.5.3 AbbVie Inc Therapies and Diagnostics for Ovarian Cancer Product and Solutions
2.5.4 AbbVie Inc Therapies and Diagnostics for Ovarian Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 AbbVie Inc Recent Developments and Future Plans
2.6 Celgene
2.6.1 Celgene Details
2.6.2 Celgene Major Business
2.6.3 Celgene Therapies and Diagnostics for Ovarian Cancer Product and Solutions
2.6.4 Celgene Therapies and Diagnostics for Ovarian Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Celgene Recent Developments and Future Plans
2.7 Janssen Pharmaceuticals
2.7.1 Janssen Pharmaceuticals Details
2.7.2 Janssen Pharmaceuticals Major Business
2.7.3 Janssen Pharmaceuticals Therapies and Diagnostics for Ovarian Cancer Product and Solutions
2.7.4 Janssen Pharmaceuticals Therapies and Diagnostics for Ovarian Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Janssen Pharmaceuticals Recent Developments and Future Plans
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business
2.8.3 Merck Therapies and Diagnostics for Ovarian Cancer Product and Solutions
2.8.4 Merck Therapies and Diagnostics for Ovarian Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Merck Recent Developments and Future Plans
2.9 Novartis AG
2.9.1 Novartis AG Details
2.9.2 Novartis AG Major Business
2.9.3 Novartis AG Therapies and Diagnostics for Ovarian Cancer Product and Solutions
2.9.4 Novartis AG Therapies and Diagnostics for Ovarian Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Novartis AG Recent Developments and Future Plans
2.10 Quest Diagnostics Inc
2.10.1 Quest Diagnostics Inc Details
2.10.2 Quest Diagnostics Inc Major Business
2.10.3 Quest Diagnostics Inc Therapies and Diagnostics for Ovarian Cancer Product and Solutions
2.10.4 Quest Diagnostics Inc Therapies and Diagnostics for Ovarian Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Quest Diagnostics Inc Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Therapies and Diagnostics for Ovarian Cancer Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Therapies and Diagnostics for Ovarian Cancer Players Market Share
3.2.2 Top 10 Therapies and Diagnostics for Ovarian Cancer Players Market Share
3.2.3 Market Competition Trend
3.3 Therapies and Diagnostics for Ovarian Cancer Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Therapies and Diagnostics for Ovarian Cancer Revenue and Market Share by Type (2016-2021)
4.2 Global Therapies and Diagnostics for Ovarian Cancer Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Application (2016-2021)
5.2 Therapies and Diagnostics for Ovarian Cancer Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2016-2026)
6.2 North America Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2016-2026)
6.3 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Country
6.3.1 North America Therapies and Diagnostics for Ovarian Cancer Revenue by Country (2016-2026)
6.3.2 United States Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
6.3.3 Canada Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
6.3.4 Mexico Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2016-2026)
7.2 Europe Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2016-2026)
7.3 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Country
7.3.1 Europe Therapies and Diagnostics for Ovarian Cancer Revenue by Country (2016-2026)
7.3.2 Germany Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
7.3.3 France Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
7.3.5 Russia Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
7.3.6 Italy Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2016-2026)
8.2 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2016-2026)
8.3 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Region
8.3.1 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Revenue by Region (2016-2026)
8.3.2 China Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
8.3.3 Japan Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
8.3.4 South Korea Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
8.3.5 India Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
8.3.7 Australia Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2016-2026)
9.2 South America Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2016-2026)
9.3 South America Therapies and Diagnostics for Ovarian Cancer Market Size by Country
9.3.1 South America Therapies and Diagnostics for Ovarian Cancer Revenue by Country (2016-2026)
9.3.2 Brazil Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
9.3.3 Argentina Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2016-2026)
10.2 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2016-2026)
10.3 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Country
10.3.1 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue by Country (2016-2026)
10.3.2 Turkey Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
10.3.4 UAE Therapies and Diagnostics for Ovarian Cancer Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Therapies and Diagnostics for Ovarian Cancer Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Therapies and Diagnostics for Ovarian Cancer Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Therapies and Diagnostics for Ovarian Cancer Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million) by Region (2016-2021)
Table 5. Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Region (2021-2026)
Table 6. Astra Zeneca Corporate Information, Head Office, and Major Competitors
Table 7. Astra Zeneca Major Business
Table 8. Astra Zeneca Therapies and Diagnostics for Ovarian Cancer Product and Solutions
Table 9. Astra Zeneca Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Clovis Oncology Corporate Information, Head Office, and Major Competitors
Table 11. Clovis Oncology Major Business
Table 12. Clovis Oncology Therapies and Diagnostics for Ovarian Cancer Product and Solutions
Table 13. Clovis Oncology Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Myriad Corporate Information, Head Office, and Major Competitors
Table 15. Myriad Major Business
Table 16. Myriad Therapies and Diagnostics for Ovarian Cancer Product and Solutions
Table 17. Myriad Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. TESARO Corporate Information, Head Office, and Major Competitors
Table 19. TESARO Major Business
Table 20. TESARO Therapies and Diagnostics for Ovarian Cancer Product and Solutions
Table 21. TESARO Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. AbbVie Inc Corporate Information, Head Office, and Major Competitors
Table 23. AbbVie Inc Major Business
Table 24. AbbVie Inc Therapies and Diagnostics for Ovarian Cancer Product and Solutions
Table 25. AbbVie Inc Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Celgene Corporate Information, Head Office, and Major Competitors
Table 27. Celgene Major Business
Table 28. Celgene Therapies and Diagnostics for Ovarian Cancer Product and Solutions
Table 29. Celgene Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Janssen Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 31. Janssen Pharmaceuticals Major Business
Table 32. Janssen Pharmaceuticals Therapies and Diagnostics for Ovarian Cancer Product and Solutions
Table 33. Janssen Pharmaceuticals Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Merck Corporate Information, Head Office, and Major Competitors
Table 35. Merck Major Business
Table 36. Merck Therapies and Diagnostics for Ovarian Cancer Product and Solutions
Table 37. Merck Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 39. Novartis AG Major Business
Table 40. Novartis AG Therapies and Diagnostics for Ovarian Cancer Product and Solutions
Table 41. Novartis AG Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Quest Diagnostics Inc Corporate Information, Head Office, and Major Competitors
Table 43. Quest Diagnostics Inc Major Business
Table 44. Quest Diagnostics Inc Therapies and Diagnostics for Ovarian Cancer Product and Solutions
Table 45. Quest Diagnostics Inc Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million) by Players (2019-2021)
Table 47. Global Therapies and Diagnostics for Ovarian Cancer Revenue Share by Players (2019-2021)
Table 48. Breakdown of Therapies and Diagnostics for Ovarian Cancer by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Therapies and Diagnostics for Ovarian Cancer Players Head Office, Products and Services Provided
Table 50. Therapies and Diagnostics for Ovarian Cancer Mergers & Acquisitions in the Past Five Years
Table 51. Therapies and Diagnostics for Ovarian Cancer New Entrants and Expansion Plans
Table 52. Global Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million) by Type (2016-2021)
Table 53. Global Therapies and Diagnostics for Ovarian Cancer Revenue Share by Type (2016-2021)
Table 54. Global Therapies and Diagnostics for Ovarian Cancer Revenue Forecast by Type (2021-2026)
Table 55. Global Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2016-2021)
Table 56. Global Therapies and Diagnostics for Ovarian Cancer Revenue Forecast by Application (2021-2026)
Table 57. North America Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Therapies and Diagnostics for Ovarian Cancer Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Therapies and Diagnostics for Ovarian Cancer Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Therapies and Diagnostics for Ovarian Cancer Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Therapies and Diagnostics for Ovarian Cancer Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Therapies and Diagnostics for Ovarian Cancer Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Therapies and Diagnostics for Ovarian Cancer Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Therapies and Diagnostics for Ovarian Cancer Picture
Figure 2. Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Type in 2020
Figure 3. Surgery
Figure 4. Radiation Therapy
Figure 5. Drug Treatment
Figure 6. Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Application in 2020
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Others Picture
Figure 10. Global Therapies and Diagnostics for Ovarian Cancer Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Therapies and Diagnostics for Ovarian Cancer Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Region (2016-2026)
Figure 13. Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Region in 2020
Figure 14. North America Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Middle East and Africa Therapies and Diagnostics for Ovarian Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Therapies and Diagnostics for Ovarian Cancer Market Drivers
Figure 20. Therapies and Diagnostics for Ovarian Cancer Market Restraints
Figure 21. Therapies and Diagnostics for Ovarian Cancer Market Trends
Figure 22. Astra Zeneca Recent Developments and Future Plans
Figure 23. Clovis Oncology Recent Developments and Future Plans
Figure 24. Myriad Recent Developments and Future Plans
Figure 25. TESARO Recent Developments and Future Plans
Figure 26. AbbVie Inc Recent Developments and Future Plans
Figure 27. Celgene Recent Developments and Future Plans
Figure 28. Janssen Pharmaceuticals Recent Developments and Future Plans
Figure 29. Merck Recent Developments and Future Plans
Figure 30. Novartis AG Recent Developments and Future Plans
Figure 31. Quest Diagnostics Inc Recent Developments and Future Plans
Figure 32. Global Therapies and Diagnostics for Ovarian Cancer Revenue Share by Players in 2020
Figure 33. Therapies and Diagnostics for Ovarian Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players Therapies and Diagnostics for Ovarian Cancer Revenue Market Share in 2020
Figure 35. Global Top 10 Players Therapies and Diagnostics for Ovarian Cancer Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global Therapies and Diagnostics for Ovarian Cancer Revenue Share by Type in 2020
Figure 38. Global Therapies and Diagnostics for Ovarian Cancer Market Share Forecast by Type (2021-2026)
Figure 39. Global Therapies and Diagnostics for Ovarian Cancer Revenue Share by Application in 2020
Figure 40. Global Therapies and Diagnostics for Ovarian Cancer Market Share Forecast by Application (2021-2026)
Figure 41. North America Therapies and Diagnostics for Ovarian Cancer Sales Market Share by Type (2016-2026)
Figure 42. North America Therapies and Diagnostics for Ovarian Cancer Sales Market Share by Application (2016-2026)
Figure 43. North America Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Country (2016-2026)
Figure 44. United States Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Therapies and Diagnostics for Ovarian Cancer Sales Market Share by Type (2016-2026)
Figure 48. Europe Therapies and Diagnostics for Ovarian Cancer Sales Market Share by Application (2016-2026)
Figure 49. Europe Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Country (2016-2026)
Figure 50. Germany Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Region (2016-2026)
Figure 58. China Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Therapies and Diagnostics for Ovarian Cancer Sales Market Share by Type (2016-2026)
Figure 65. South America Therapies and Diagnostics for Ovarian Cancer Sales Market Share by Application (2016-2026)
Figure 66. South America Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa Therapies and Diagnostics for Ovarian Cancer Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa Therapies and Diagnostics for Ovarian Cancer Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE Therapies and Diagnostics for Ovarian Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
卵巣がん治療＆診断の世界市場 2019年版：種類別（手術、放射線療法、薬物治療）、用途別（病院、クリニック、その他） Scope of the Report: The global Therapies and Diagnostics for Ovarian Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, e…- 世界の卵巣がん診断技術市場 2021：企業別、地域別、種類・用途別 The Ovarian Cancer Diagnostics Technologies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…
- 世界の上皮性卵巣がん治療市場 2021：企業別、地域別、種類・用途別 The Epithelial Ovarian Cancer Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…
- 世界の卵巣がん治療薬市場 2021：企業別、地域別、種類・用途別 The Ovarian Cancer Treatment Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade …
- 世界のがん治療用遺伝子治療市場予測（～2024年） Gene therapy is the therapeutic delivery of nucleic acid into a patient's cells as a drug to treat disease. Research in gene therapy for cancer is currently focused in multiple areas, including genetically engineered viruses that directly kill cancer cells, gene transfer to alter the abnormal functi…